Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-10-28 Call Transcript
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an earnings conference call held on October 24, 2024, discussing the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2024. It includes detailed management commentary, financial highlights, business updates, and a Q&A session with analysts. The presence of forward-looking statements, detailed financial figures, and management discussion confirms this is a full transcript of the earnings call rather than a brief earnings release or summary. Therefore, the document fits the definition of a Call Transcript (CT).
2024-10-28 English
Copy of Newspaper Publication
Regulatory Filings
2024-10-25 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the availability of an audio recording of an earnings conference call for the quarter and half year ended 30th September 2024. It references the unaudited standalone and consolidated financial results but does not contain the financial results itself, only announcing the availability of the call recording on the company's website. The document length is short (1600 characters), and it serves as an announcement rather than the transcript or the financial report. Therefore, it fits the category of a Call Transcript announcement or related notice. However, since it only announces the availability of the audio recording and does not provide the transcript text, the best fit is Regulatory Filings (RNS) as a general announcement. The document is not the full transcript (CT) nor the earnings release (ER) itself, but an announcement about the call recording.
2024-10-24 English
Investor Presentation
Investor Presentation Classification · 100% confidence The document is titled as an "Investor Presentation" and is addressed to stock exchanges pursuant to SEBI regulations. It contains detailed financial highlights, business overview, segment performance, geographical footprint, quarterly and half-year financial data, and market information. The document is about unaudited standalone and consolidated financial results for the quarter and half year ended 30th September 2024. It is a presentation format rather than a formal report like an annual or interim report. The length is substantial (15,000 characters), and it contains detailed financial and business information typical of an investor presentation. Therefore, the document fits the category of Investor Presentation (IP).
2024-10-24 English
Financial Result Updates
Regulatory Filings
2024-10-24 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an announcement from Indoco Remedies Limited regarding an upcoming earnings conference call for the unaudited financial results for the quarter and half year ended September 30, 2024. It includes details about the date, time, and participants of the call, as well as dial-in information and contacts for further inquiries. The document does not contain actual financial statements or substantive financial data but serves to inform about the scheduling of the earnings call. Therefore, it is not the earnings release itself but an announcement related to the earnings call. Given the content and length (2522 characters), this fits best under the category of a Call Transcript (CT) announcement or an Earnings Release (ER) announcement. However, since it is specifically about the earnings conference call and not the earnings release, the most appropriate classification is Call Transcript (CT) as it pertains to the earnings call event.
2024-10-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.